Implemed Olimpicc antimicrobial CVC catheter study gets funding from AmHS/Premier/SunHealth.
This article was originally published in The Gray Sheet
Executive Summary
IMPLEMED OLIMPICC ANTIMICROBIAL CENTRAL VENOUS CATHETER TRIALS are slated to begin during the next several weeks, the company says. Implemed received an investigational device exemption Dec. 8 to study the peripherally inserted catheter's antimicrobial performance, as well as its general safety and efficacy, the firm says.
You may also be interested in...
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Stakeholders Devise Six-Point Plan To Improve Cross-Border Clinical Trials
Sponsors need guidance on ethics requirements and clarity around national regulations to conduct cross-border clinical trials in the EU, a multi-stakeholder forum says.